Innovative drugs for motion sickness

On May 15, Vanda Pharmaceuticals, a US biopharmaceutical company, announced that the second Phase III study of its new drug Tradipitant (tradipitant) for the treatment of motion sickness (especially motion sickness) has achieved positive results.
Tradipitant is a neurokinin-1 (NK1) receptor antagonist developed by Eli Lilly. Vanda obtained the global development rights of Tradipitant through licensing in April 2012.
Currently, Vanda has developed Tradipitant for indications such as atopic dermatitis pruritus, gastroparesis, new coronavirus infection, motion sickness, alcohol addiction, social phobia, and indigestion.
This Phase 3 study included 316 motion sickness patients with a history of motion sickness, who were treated with 170 mg Tradipitant, 85 mg Tradipitant, or placebo during a boat trip.
All study participants had a history of seasickness. The primary endpoint of the study was the effect of tradipitant (170 mg) on ​​vomiting. The key secondary endpoints are: (1) the effect of tradipitant (85 mg) on ​​vomiting; (2) the effect of tradipitant in preventing severe nausea and vomiting.
It is reported that motion sickness remains an unmet medical need. The U.S. Food and Drug Administration (FDA) has not approved a new drug for the treatment of motion sickness for more than 40 years since it approved scopolamine (a transdermal patch placed behind the ear) in 1979.

Based on the data from the two Phase III studies, Vanda will submit a marketing application for tradipitant to the FDA for the treatment of motion sickness in the fourth quarter of 2024.